Immune system discovery could help researchers further understand type 1 diabetes

Australian scientists have been studying one specific cell type called CD4+ T cell which initiates the immune system response that characterises type 1 diabetes.

The CD4+ T cells recognise a part of the insulin-producing beta cells as foreign invaders, and attack them.

When blood was taken from the arms of people with newly-diagnosed type 1 diabetes, the blood contained T cells that recognised C-peptide, a precursor of how much insulin your body is producing.

C-peptide was recognised by CD4+ T cells in more than 60% of participants with type 1 diabetes, but in less than 10% of people without type 1 diabetes. Moreover, the proteins in the body which recognised C-peptide are associated with an increased type 1 diabetes risk.

The University of Melbourne researchers said: "Our study shows that the T cells respond most robustly to the full-length C-peptide. This points to C-peptide being an important, clinically relevant target of disease-causing CD4+ T cells in people with type 1 diabetes.

"This knowledge will allow us to begin to develop preventative therapies to stop the aberrant immune response before it does irreversible damage."

Now, the researchers hope the discovery could be used to inhibit progression of type 1 diabetes among people at high risk.

"Our results will allow the development of blood tests to determine whether a person is likely to get type 1 diabetes and to measure how well a therapy to stop the progression of the disease is working."

In recent years Iran branch of Vitane was established with main focus on manufacturing biologics, special treatment and orphan drugs. The production site of the company will be opened in this year with some products which are entered to domestic market through contract manufacturing. CONTACT US »

VITANE PHARMA:
ویتان فارمد

With in headquarters in Germany , the company has entered into manufacturing alliances with leading pharmaceutical manufacturers in the U.S., Europe, Asia and Middle East.